Ivermectin News and Research

RSS

Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic medication. It is traditionally used against worms, but more recently found to be effective against mites and some lice too. Ivermectin is currently being used to help eliminate river blindness (onchocerciasis) in the Americas and stop transmission of lymphatic filariasis around the world.

FDA grants approval of nonprescription Sklice lotion to treat head lice infestations

Today, the U.S. Food and Drug Administration approved a lotion to treat head lice for nonprescription, or over-the-counter (OTC), use through a process called a prescription (Rx)-to-OTC switch.

27 Oct 2020

Nasal spray formulation of ivermectin for COVID-19 shows promise in pigs

Researchers in Argentina have conducted a pre-clinical study demonstrating the safety and pharmacokinetic performance of a new nasal spray formulation designed to suppress the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

26 Oct 2020

New inhibitor of SARS-CoV-2 RNA translation

As the search for effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibitors continues, a recent study by Yale University School of Medicine researchers published on the preprint server bioRxiv in October 2020 reports the inhibitory effect of the drug merofloxacin on frameshifting during SARS-CoV-2 replication.

26 Oct 2020

Certain live-attenuated vaccines can prevent severe complications of COVID-19

COVID-19 continues to wreak havoc globally, with over one million deaths to date. Yet what if an existing vaccine could make COVID-19 less deadly? A study just published put the theory to test, with promising results.

15 Oct 2020

New method spurs production of antibiotic or antiparasitic compounds in actinobacteria

Researchers have developed a method to spur the production of new antibiotic or antiparasitic compounds hiding in the genomes of actinobacteria, which are the source of drugs such as actinomycin and streptomycin and are known to harbor other untapped chemical riches.

25 Jun 2020

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.

22 Jun 2020

Repurposing immunosuppressants to manage COVID-19

It might seem paradoxical to suggest immunosuppression could play a role in managing COVID-19. The seemingly logical therapeutic option for this disease would be an antiviral.

18 Jun 2020

Researchers receive $5 million to study two types of parasitic infection

Researchers at Washington University School of Medicine in St. Louis have received two grants from the National Institutes of Health totaling more than $5 million to study two types of parasitic worm infection that cause devastating illness in millions of people worldwide.

21 May 2020

New clinical trial to investigate the efficacy of ivermectin against COVID-19

Clínica Universidad de Navarra and the Barcelona Institute for Global Health (ISGlobal), a centre supported by the "la Caixa" Foundation, have launched a clinical trial to investigate the efficacy of ivermectin against COVID-19.

14 May 2020

Clinical trial launched to evaluate experimental COVID-19 therapies

Clinical leaders from the University of Kentucky's Markey Cancer Center, College of Medicine and College of Pharmacy have launched a clinical trial for experimental therapies to treat patients infected with COVID-19.

11 May 2020

French scientists suggest nicotinic agonists could treat COVID-19

Contrary to the warnings issued by health agencies worldwide against cigarette smoking amid the coronavirus disease (COVID-19), a new paper suggests the possibility that nicotine, a component of tobacco, could prevent coronavirus infection.

28 Apr 2020

The approved dose of ivermectin alone not useful in treating COVID-19

A new paper published on the preprint server medRxiv in April 2020 shows that the use of the already approved drug ivermectin in clinical trials to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)s not feasible. This contradicts earlier reports of its ability to suppress the virus in vitro.

27 Apr 2020

Antiparasitic drug Ivermectin kills coronavirus in 48 hours

Around the world, scientists race to develop a vaccine or treatment against the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Now, a team of researchers has found that a drug already available around the world can kill the coronavirus in a lab setting in just 48 hours.

6 Apr 2020

Australian scientists identify possible coronavirus drug

A collaborative study led by Monash University's Biomedicine Discovery Institute in Melbourne, Australia, with the Peter Doherty Institute of Infection and Immunity, has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours.

3 Apr 2020

'African eye worm' hampers efforts to eliminate river blindness, study shows

Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or 'African eye worm,' according to a study published in Clinical Infectious Diseases.

20 Nov 2019

Scientists create new models of tropical eye worm for development of anti-filarial drugs

Researchers at the LSTM's Centre for Drugs and Diagnostics, and University of Buea, Cameroon have developed new models of the tropical eye worm, Loa loa for the development of new drugs against filariasis.

30 Mar 2019

WHO revise treatment guidelines of lymphatic filariasis due to CWRU-led study

Researchers from Case Western Reserve University School of Medicine have shown that a single "cocktail" of three pill-based anti-parasite medications is significantly more effective at killing microscopic larval worms in people diagnosed with lymphatic filariasis, commonly known as elephantiasis, than other standard two-drug combinations previously used in the global effort to eliminate this infectious disease.

9 Nov 2018

University of Alicante study: Antiparasitic Ivermectin six times more toxic than Moxidectin

Ivermectin is six times more toxic than Moxidectin for insects in charge of the recycling of organic matter. For the first time ever, there is scientific evidence based on physiological studies and this should be taken into account when using antiparasitic agents for livestock.

25 Oct 2018

Scientists develop urine diagnostic to detect parasitic worms that cause river blindness

Scientists at Scripps Research have developed a urine diagnostic to detect the parasitic worms that cause river blindness, also called onchocerciasis, a tropical disease that afflicts 18 to 120 million people worldwide.

28 Aug 2018

Researchers use smartphone to diagnose people infected with Loa loa worm

The Berkeley researchers figured out that they could quickly determine who has the Loa loa worm using a smartphone, customized to work like a microscope. They could then skip the medication for those people and give it to everyone else. Kamgno, who received the latest version of the phones in 2016, dubbed the mobile microscopes "revolutionary."

19 Apr 2018